JPRN-UMIN000006793
Recruiting
Phase 2
Multicenter phase II study of combination chemotherapy with IRIS and Cetuximab as second line therapy in patient with colorectal cancer - Multicenter phase II study of combination chemotherapy with IRIS and Cetuximab as second line therapy in patient with colorectal cancer
ippon Medical School Musashikosugi Hospital0 sites40 target enrollmentDecember 1, 2011
Conditionscolorectal cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- colorectal cancer
- Sponsor
- ippon Medical School Musashikosugi Hospital
- Enrollment
- 40
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) History of severe allergy 2\) Simultaneous or metachronous double cancers 3\) active infectious disease, 4\) Severe comorbidity 5\) Massive pleural effusion or ascites 6\) Wattery diarrhea 7\) Paralytic or mechanical bowel obstruction 8\) Symptomatic brain metastasis 9\) Patients who is receiving Fluorocytosine or Atazanavir Sulfate 10\) Pregnant or lactating women or women of childbearing potential. 11\) Amalgamation of mental disease or psychotic manifestation 12\) Patients who are inadequate by investigator's decision.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A Phase II study of combination chemotherapy including Bortezomib in pediatric patients with relapsed acute lymphoblastic leukemia (Investigator-initiated clinical trial)A high-risk group of pediatric patients with first relapse of ALLor refractory ALL (patients who develop 2nd or subsequent relapse, relapse after hematopoietic cell transplantation or fail to achieve remission induction with one or more therapies).JPRN-UMIN000023815Department of Pediatric Oncology, National Cancer Center Hospital22
Completed
Phase 2
Phase II clinical study of the combination chemotherapy regimen of topotecan plus oral etoposide for the treatment of recurrent ovarian cancerResistant ovarian cancerJPRN-UMIN000007318Kyorin University, School of Medicine20
Completed
Phase 2
Multicenter phase II study of combination therapy with oral S-1 plus cisplatin in elderly patients with metastatic gastric cancerElderly patients with metastatic gastric cancerJPRN-UMIN000009349ational Cancer Center Hospital40
Completed
Phase 2
Multicenter Phase II study of combination therapy with S-1 plus Irinotecan plus Cetuximab (MetronomicIRIS/Cmab combination therapy) in patients with KRAS wild type unresectable colorectal cancer, who had previously received on fluoropyrimidine , oxaliplatin , irinotecan and bevacizumab. (KSCOG CR-06)Colorectal cancerJPRN-UMIN000012063Kurume University Medical Center30
Completed
Phase 2
Multi-center, phase II study for combination therapy with weekly pacritaxel and 5'-DFUR in patients with unresectable or recurrent gastric cancerAdvanced or recurrent gastric cancerJPRN-UMIN000008631Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine45